RATIONALE: Only a small percentage of individuals seeking treatment for their marijuana use achieves sustained abstinence, suggesting more treatment options are needed. OBJECTIVES: We investigated the effects of baclofen (study 1) and mirtazapine (study 2) in a human laboratory model of marijuana intoxication, withdrawal, and relapse. METHODS: In study 1, daily marijuana smokers (n = 10), averaging 9.4 (+/-3.9) marijuana cigarettes/day, were maintained on placebo and each baclofen dose (60, 90 mg/day) for 16 days. In study 2, daily marijuana smokers (n = 11), averaging 11.9 (+/-5.3) marijuana cigarettes/day, were maintained on placebo and mirtazapine (30 mg/day) for 14 days each. Medication administration began outpatient prior to each 8-day inpatient phase. On the first inpatient day of each medication condition, participants smoked active marijuana (study 1: 3.3% THC; study 2: 6.2% THC). For the next 3 days, they could self-administer placebo marijuana (abstinence phase), followed by 4 days in which they could self-administer active marijuana (relapse phase); participants paid for self-administered marijuana using study earnings. RESULTS: In study 1, during active marijuana smoking, baclofen dose-dependently decreased craving for tobacco and marijuana, but had little effect on mood during abstinence and did not decrease relapse. Baclofen also worsened cognitive performance regardless of marijuana condition. In study 2, mirtazapine improved sleep during abstinence, and robustly increased food intake, but had no effect on withdrawal symptoms and did not decrease marijuana relapse. CONCLUSIONS: Overall, this human laboratory study did not find evidence to suggest that either baclofen or mirtazapine showed promise for the potential treatment of marijuana dependence.
RCT Entities:
RATIONALE: Only a small percentage of individuals seeking treatment for their marijuana use achieves sustained abstinence, suggesting more treatment options are needed. OBJECTIVES: We investigated the effects of baclofen (study 1) and mirtazapine (study 2) in a human laboratory model of marijuana intoxication, withdrawal, and relapse. METHODS: In study 1, daily marijuana smokers (n = 10), averaging 9.4 (+/-3.9) marijuana cigarettes/day, were maintained on placebo and each baclofen dose (60, 90 mg/day) for 16 days. In study 2, daily marijuana smokers (n = 11), averaging 11.9 (+/-5.3) marijuana cigarettes/day, were maintained on placebo and mirtazapine (30 mg/day) for 14 days each. Medication administration began outpatient prior to each 8-day inpatient phase. On the first inpatient day of each medication condition, participants smoked active marijuana (study 1: 3.3% THC; study 2: 6.2% THC). For the next 3 days, they could self-administer placebo marijuana (abstinence phase), followed by 4 days in which they could self-administer active marijuana (relapse phase); participants paid for self-administered marijuana using study earnings. RESULTS: In study 1, during active marijuana smoking, baclofen dose-dependently decreased craving for tobacco and marijuana, but had little effect on mood during abstinence and did not decrease relapse. Baclofen also worsened cognitive performance regardless of marijuana condition. In study 2, mirtazapine improved sleep during abstinence, and robustly increased food intake, but had no effect on withdrawal symptoms and did not decrease marijuana relapse. CONCLUSIONS: Overall, this human laboratory study did not find evidence to suggest that either baclofen or mirtazapine showed promise for the potential treatment of marijuana dependence.
Authors: John Liappas; Thomas Paparrigopoulos; Elias Tzavellas; Andreas Rabavilas Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2004-11-23 Impact factor: 5.067
Authors: Dagmar A Schmid; Adam Wichniak; Manfred Uhr; Marcus Ising; Hans Brunner; Katja Held; Jutta C Weikel; Annette Sonntag; Axel Steiger Journal: Neuropsychopharmacology Date: 2006-04 Impact factor: 7.853
Authors: Margaret Haney; Ziva D Cooper; Gillinder Bedi; Evan Herrmann; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin; Frances R Levin Journal: Addict Biol Date: 2018-04-16 Impact factor: 4.280
Authors: Ziva D Cooper; Richard W Foltin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Margaret Haney Journal: Addict Biol Date: 2012-06-28 Impact factor: 4.280
Authors: David J Allsop; Delwyn J Bartlett; Jennifer Johnston; David Helliwell; Adam Winstock; Iain S McGregor; Nicholas Lintzeris Journal: J Clin Sleep Med Date: 2015-10-15 Impact factor: 4.062
Authors: Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: Neuropsychopharmacology Date: 2013-02-26 Impact factor: 7.853